Ofatumumab

Category: Cancer



Ofatumumab Overview

Ofatumumab,[7] sold under the brand name Arzerra among others, is a fully human monoclonal antibody to CD20, which appears to inhibit early-stage B lymphocyte activation. It is FDA approved for treating chronic lymphocytic leukemia that is refractory to fludarabine and alemtuzumab (Campath) and for the treatment of multiple sclerosis. It has also shown potential in treating follicular lymphoma, diffuse large B cell lymphoma, rheumatoid arthritis. Ofatumumab is the first market...

Read more Ofatumumab Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Ofatumumab

Recent Ofatumumab Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Ofatumumab
  • Injection: 100mg/5ml
  • Solution: 20mg/0.4ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Ofatumumab: (1 result)

Sorted by National Drug Code
  • 0078-1007 Kesimpta 20 mg/.4ml Subcutaneous Injection, Solution by Novartis Pharmaceuticals Corporation

Other drugs which contain Ofatumumab or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 27 November 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA